-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
iNature non-alcoholic steatohepatitis (NASH) is the advanced stage of non-alcoholic fatty liver disease (NAFLD), affecting approximately 6% of the world’s population, and is closely related to abnormal cardiometabolics, which sharply increases the risk of late-stage liver disease and extrahepatic symptoms .
Despite the importance of NASH, the FDA has not approved NASH-specific drugs.
G protein-coupled receptor (GPCR) represents the largest targetable drug in the human genome, and it strongly regulates pathophysiological events.
Recent structural and molecular studies have further expanded the classical pharmacological applications of GPCRs and enabled the use of emerging GPCR agonists or antagonists to treat metabolic diseases.
These advances have encouraged new insights into the development of NASH therapies that target GPCRs.
On April 7, 2021, Zhe Zhigang and Li Hongliang of Wuhan University jointly published a review article titled "Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis" in Hepatology.
The review analyzed the latest reports of GPCRs in NASH.
And discussed the trend of using GPCR as a therapeutic target for NASH.
In addition, in 2020, Li Hongliang's team at Wuhan University published more than 20 high-level research results (click to read).
Hormones are considered to be the only therapeutic drug that can effectively reduce the mortality of patients with new coronary pneumonia, but the role of hormones in improving the clinical outcome and reducing mortality of patients with new coronary pneumonia has always been very uncertain.
During the SARS period in 2003, hormone drugs have treated a large number of patients, but they also brought serious complications such as femoral head necrosis.
Based on previous lessons, hormones have always been a huge controversy in the treatment of new coronary pneumonia.In the early stage of the epidemic, the attitude towards hormone therapy was clearly divided into two groups: one group believed that hormones should be used as soon as possible; the other group believed that hormones do more harm than good.
Support the view that: hormones have significant anti-inflammatory effects.
When patients have severe inflammatory reactions, using hormones can help suppress inflammatory secretions, enhance lung function, and reduce patient mortality.
The opposing view is that the use of high-dose hormone therapy in patients with new coronary pneumonia has the risk of secondary infection, prolonged virus clearance, and increased blood sugar.
In the diagnosis and treatment of new coronary pneumonia, my country has shown a cautious attitude towards the use of glucocorticoid drugs from the beginning, and there are stricter restrictions on the use of hormones.
Internationally, the WHO has expressed its opposition in the early stage.
Between July and September 2020, the results of clinical trials on whether the use of hormones in patients with new crowns is beneficial has been released one after another, suggesting that hormones have a significant protective effect on critically ill patients.
On September 2, 2020, after a prospective meta-analysis of randomized clinical trials, WHO issued new guidelines for the use of hormones: It is strongly recommended that systemic glucocorticoids be used for the treatment of severe and critically ill patients with new coronary pneumonia.
Conditional recommendations for the treatment of non-severe cases Glucocorticoids are not used in patients with new coronary pneumonia.
However, there are no clear, objective, and quantifiable indicators for the interpretation of severe cases in the guidelines, and clinicians are still very confused about when to use hormones.
Therefore, clarifying the "use boundary" of hormone drugs as soon as possible is an urgent clinical problem in the treatment of new coronary pneumonia.
In response to this urgent clinical problem, the study collected clinical data of patients with new crowns in 21 hospitals in Hubei Province and established a database of more than 15,000 patients with new crowns (this is also one of the largest databases of patients with new crowns in the world).
Through rigorous modeling calculations, analysis, and verification, the research team found that the "neutrophil-lymphocyte ratio (NLR)" is closely related to the death risk of new coronary patients and whether the use of hormones benefits.
When the NLR value is higher than 6.
11, the use of hormones is significantly related to reducing mortality and improving the prognosis; when the NLR value is lower than 6.
11, the use of hormones will not only not benefit, but will increase the risk of hyperglycemia and infection. New coronary pneumonia combined with diabetes will significantly increase the mortality of patients, and a side effect of hormones that cannot be ignored is the increase in blood sugar.
The study further analyzed the effects of hormone use on mortality and treatment effects in diabetic patients.
It was found that the use of hormones in diabetic patients could not significantly reduce mortality or improve treatment effects, but would increase the side effects of secondary infections and increased blood sugar.
The article model diagram (pictured from Cell Metabolism) is a significant research result.
It is the first clear answer for the treatment of new coronary pneumonia.
Under what circumstances can patients with new coronary pneumonia use hormone therapy to obtain the greatest benefits and help better Guide clinical hormone medication.
Moreover, NLR is also one of the most easily obtained blood routine data.
Its clinical use is simple, efficient, and easy to use.
It has clear and important guiding significance for the clinical use of hormone drugs.
At present, the new crown epidemic is still in a period of global pandemic, seriously threatening the lives and health of people in all countries.
Hormones are currently the only therapy that can significantly reduce the mortality of patients, but there is a lack of clear, objective and quantifiable indicators to define which patients are used.
The publication of the research results will help clinicians to more accurately determine when to use hormones.
Reference message:
Despite the importance of NASH, the FDA has not approved NASH-specific drugs.
G protein-coupled receptor (GPCR) represents the largest targetable drug in the human genome, and it strongly regulates pathophysiological events.
Recent structural and molecular studies have further expanded the classical pharmacological applications of GPCRs and enabled the use of emerging GPCR agonists or antagonists to treat metabolic diseases.
These advances have encouraged new insights into the development of NASH therapies that target GPCRs.
On April 7, 2021, Zhe Zhigang and Li Hongliang of Wuhan University jointly published a review article titled "Therapeutic Potential of G Protein-Coupled Receptors against Nonalcoholic Steatohepatitis" in Hepatology.
The review analyzed the latest reports of GPCRs in NASH.
And discussed the trend of using GPCR as a therapeutic target for NASH.
In addition, in 2020, Li Hongliang's team at Wuhan University published more than 20 high-level research results (click to read).
Hormones are considered to be the only therapeutic drug that can effectively reduce the mortality of patients with new coronary pneumonia, but the role of hormones in improving the clinical outcome and reducing mortality of patients with new coronary pneumonia has always been very uncertain.
During the SARS period in 2003, hormone drugs have treated a large number of patients, but they also brought serious complications such as femoral head necrosis.
Based on previous lessons, hormones have always been a huge controversy in the treatment of new coronary pneumonia.In the early stage of the epidemic, the attitude towards hormone therapy was clearly divided into two groups: one group believed that hormones should be used as soon as possible; the other group believed that hormones do more harm than good.
Support the view that: hormones have significant anti-inflammatory effects.
When patients have severe inflammatory reactions, using hormones can help suppress inflammatory secretions, enhance lung function, and reduce patient mortality.
The opposing view is that the use of high-dose hormone therapy in patients with new coronary pneumonia has the risk of secondary infection, prolonged virus clearance, and increased blood sugar.
In the diagnosis and treatment of new coronary pneumonia, my country has shown a cautious attitude towards the use of glucocorticoid drugs from the beginning, and there are stricter restrictions on the use of hormones.
Internationally, the WHO has expressed its opposition in the early stage.
Between July and September 2020, the results of clinical trials on whether the use of hormones in patients with new crowns is beneficial has been released one after another, suggesting that hormones have a significant protective effect on critically ill patients.
On September 2, 2020, after a prospective meta-analysis of randomized clinical trials, WHO issued new guidelines for the use of hormones: It is strongly recommended that systemic glucocorticoids be used for the treatment of severe and critically ill patients with new coronary pneumonia.
Conditional recommendations for the treatment of non-severe cases Glucocorticoids are not used in patients with new coronary pneumonia.
However, there are no clear, objective, and quantifiable indicators for the interpretation of severe cases in the guidelines, and clinicians are still very confused about when to use hormones.
Therefore, clarifying the "use boundary" of hormone drugs as soon as possible is an urgent clinical problem in the treatment of new coronary pneumonia.
In response to this urgent clinical problem, the study collected clinical data of patients with new crowns in 21 hospitals in Hubei Province and established a database of more than 15,000 patients with new crowns (this is also one of the largest databases of patients with new crowns in the world).
Through rigorous modeling calculations, analysis, and verification, the research team found that the "neutrophil-lymphocyte ratio (NLR)" is closely related to the death risk of new coronary patients and whether the use of hormones benefits.
When the NLR value is higher than 6.
11, the use of hormones is significantly related to reducing mortality and improving the prognosis; when the NLR value is lower than 6.
11, the use of hormones will not only not benefit, but will increase the risk of hyperglycemia and infection. New coronary pneumonia combined with diabetes will significantly increase the mortality of patients, and a side effect of hormones that cannot be ignored is the increase in blood sugar.
The study further analyzed the effects of hormone use on mortality and treatment effects in diabetic patients.
It was found that the use of hormones in diabetic patients could not significantly reduce mortality or improve treatment effects, but would increase the side effects of secondary infections and increased blood sugar.
The article model diagram (pictured from Cell Metabolism) is a significant research result.
It is the first clear answer for the treatment of new coronary pneumonia.
Under what circumstances can patients with new coronary pneumonia use hormone therapy to obtain the greatest benefits and help better Guide clinical hormone medication.
Moreover, NLR is also one of the most easily obtained blood routine data.
Its clinical use is simple, efficient, and easy to use.
It has clear and important guiding significance for the clinical use of hormone drugs.
At present, the new crown epidemic is still in a period of global pandemic, seriously threatening the lives and health of people in all countries.
Hormones are currently the only therapy that can significantly reduce the mortality of patients, but there is a lack of clear, objective and quantifiable indicators to define which patients are used.
The publication of the research results will help clinicians to more accurately determine when to use hormones.
Reference message:
